Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.230
-0.010-0.11%
Volume:59.56M
Turnover:549.93M
Market Cap:106.35B
PE:23.29
High:9.320
Open:9.130
Low:9.110
Close:9.240
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.46
T/O Rate:0.52%
Dividend:0.29
Dividend Rate:3.14%
EPS(LYR):0.396
ROE:20.90%
ROA:10.70%
PB:2.42
PE(LYR):23.29
PS:2.91

Loading ...

CSPC PHARMA: DFZQ Disposes of Shares, Long Position Falls to 4.93%

HK Disclosure
·
Aug 27

CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus

Simply Wall St.
·
Aug 27

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

MT Newswires Live
·
Aug 26

CSPC Pharma’s EGFR-Targeted ADC SYS6010 Achieves Primary PFS Endpoint in Phase III NSCLC Trial

Bulletin Express
·
Aug 26

CSPC Pharmaceutical Gains U.S. FDA Fast Track Status for Novel PD-1/IL-15 Fusion Protein in Hard-to-Treat Metastatic Colorectal Cancer

Bulletin Express
·
Aug 26

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

Stock News
·
Aug 26

CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer

Reuters
·
Aug 26

CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients

Stock News
·
Aug 26

CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 26

Sihuan Pharmaceutical H1 Profit Jumps on Medical Aesthetics Unit Strength

Reuters
·
Aug 26

Movement Alert|CSPC PHARMA Rises 3.13% in Regular Trading, RSV Vaccine Receives FDA Clinical Trial Approval While Multiple Banks Raise Target Prices

Market Focus
·
Aug 26

CSPC Pharma secures U.S. FDA clearance for Phase I trial of second recombinant RSV vaccine SYS6057

Bulletin Express
·
Aug 25

CSPC Pharma's Recombinant RSV Vaccine Wins US Clinical Trial Clearance

Stock News
·
Aug 25

CSPC Says FDA Clears RSV Vaccine Candidate SYS 6057 for US Clinical Trial

Reuters
·
Aug 25

CSPC Pharmaceutical - Recombinant Respiratory Syncytial Virus Vaccine (Sys6057) Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS
·
Aug 25

CSPC Pharmaceutical - Sys6057 Receives Nmpa Approval on July 30, 2026 to Conduct Clinical Trials in China

THOMSON REUTERS
·
Aug 25

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy

MT Newswires Live
·
Aug 24

CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 24